Role of Rho kinase in lysophosphatidic acid-induced altering of blood-brain barrier permeability

International Journal of Molecular Medicine

Volumn 33, Issue 3, 2014, Pages 661-669

  Yu, Ying ^a   Qin, Jun ^b   Liu, Meizhen ^a   Ruan, Qingyuan ^a   Li, Yiliang ^a   Zhang, Zhaohui ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Lysophosphatidic acid; Matrix metalloproteinase 9; Rho kinase; Urokinase type plasminogen activator

Indexed keywords

AMIDES; ANIMALS; BLOOD-BRAIN BARRIER; CORPUS STRIATUM; ENDOTHELIAL CELLS; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASE 9; PERMEABILITY; PYRIDINES; RATS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84893824392     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1618     Document Type: Article

References (34)

1. Moolenaar WH: Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238, 1999.
2. Van Meeteren LA, Frederiks F, Giepmans BN, et al: Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine. J Biol Chem 279: 10833-10836, 2004.
3. Tokumura A: Metabolic pathways and physiological and pathological significances of lysolipid phosphate mediators. J Cell Biochem 92: 869-881, 2004.
4. Sorensen SD, Nicole O, Peavy RD, et al: Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64: 1199-1209, 2003.
5. Tigyi G and Parrill AL: Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42: 498-526, 2003.
6. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J and Ueda H: Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152: 296-298, 2008.
7. Mauco G, Chap H, Simon MF and Douste-Blazy L: Phosphatidic and lysophosphatidic acid production in phospholipase C-and thrombin-treated platelets. Possible involvement of a platelet lipase. Biochimie 60: 653-661, 1978.
8. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M and Leffler CW: Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol 268: H2048-H2055, 1995.
9. Sun GY, Lu FL, Lin SE and Ko MR: Decapitation ischemia-induced release of free fatty acids in mouse brain. Relationship with diacylglycerols and lysophospholipids. Mol Chem Neuropathol 17: 39-50, 1992.
10. Chen KM, Liu JY, Lai SC, Hsu LS and Lee HH: Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis. Int J Exp Pathol 87: 113-119, 2006.
11. Schulze C, Smales C, Rubin LL and Staddon JM: Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem 68: 991-1000, 1997.
12. Fujii M, Duris K, Altay O, Soejima Y, Sherchan P and Zhang JH: Inhibition of Rho kinase by hydroxyfasudil attenuates brain edema after subarachnoid hemorrhage in rats. Neurochem Int 60: 327-333, 2012.
13. Liu K, Li Z, Wu T and Ding S: Role of rho kinase in microvascular damage following cerebral ischemia reperfusion in rats. Int J Mol Sci 12: 1222-1231, 2011.
14. Ishiguro M, Kawasaki K, Suzuki Y, et al: A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience 220: 302-312, 2012.
15. Jeong KJ, Park SY, Cho KH, et al: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 31: 4279-4289, 2012.
16. Baskaya MK, Dogan A, Rao AM and Dempsey RJ: Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 92: 448-452, 2000.
17. Tawara S and Shimokawa H: Progress of the study of rho-kinase and future perspective of the inhibitor. Yakugaku Zasshi 127: 501-514, 2007.
18. Huang XN, Fu J and Wang WZ: The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis. J Neuroimmunol 239: 61-67, 2011.
19. Rosenberg GA: Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8: 205-216, 2009.
20. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME and Lo EH: Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20: 1681-1689, 2000.
21. Asahi M, Wang X, Mori T, et al: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21: 7724-7732, 2001.
22. Barr TL, Latour LL, Lee KY, et al: Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 41: E123-e128, 2010.
23. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH and Montaner J: MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39: 1121-1126, 2008.
24. Romanic AM, White RF, Arleth AJ, Ohlstein EH and Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29: 1020-1030, 1998.
25. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J and Chan PH: Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19: 1020-1028, 1999.
26. Aoki T, Sumii T, Mori T, Wang X and Lo EH: Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33: 2711-2717, 2002.
27. Wang J and Tsirka SE: Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128: 1622-1633, 2005.
28. Wu H, Zhang Z, Li Y, et al: Time course of upregulation of inflammatory mediators in the hemorrhagic brain in rats: Corre-lation with brain edema. Neurochem Int 57: 248-253, 2010.
29. Dietzmann K, von Bossanyi P, Krause D, Wittig H, Mawrin C and Kirches E: Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: An immunohistochemical study. Pathol Res Pract 196: 15-21, 2000.
30. Ito T, Takenaka K, Sakai H, Yoshimura S, Hayashi K, Noda S and Sakai N: Elevation of mRNA levels of tissue-type plas-minogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats. Neurol Res 22: 413-419, 2000.
31. Armstead WM, Cines DB, Bdeir K, Kulikovskaya I, Stein SC and Higazi AA: UPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res 1231: 121-131, 2008.
32. Patel TH, Sprague S, Lai Q, Jimenez DF, Barone CM and Ding Y: Blood brain barrier (BBB) dysfunction associated with increased expression of tissue and urokinase plasminogen activators following peripheral thermal injury. Neurosci Lett 444: 222-226, 2008.
33. Park SY, Jeong KJ, Panupinthu N, et al: Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30: 1351-1359, 2011.
34. Sawada K, Morishige K, Tahara M, Ikebuchi Y, Kawagishi R, Tasaka K and Murata Y: Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol 87: 252-259, 2002.